The Orphan Drug Designation (ODD) is a status assigned by EMA to a medicine intended for use against a rare condition. The medicine must fulfil certain criteria for designation as an orphan medicine so that it can benefit from incentives such as protection from competition once on the market.
We have summarized the work process for you to have always at hand.
Have a look at the complete process:
For further information, queries or assistance, contact us at: [email protected]
Search News & Events
Share
We are pleased to announce that ASPHALION will participate in the third edition of Connection Day, organised by Catalonia.Health, which will take place on April
Starting 1st of July 2025, the AEMPS mandates the use of Organisation Management System (OMS) for all new Market Authorization Applications and variations for medicinal
The 6th General Assembly meeting of the ETERNAL project successfully wrapped up last week! Hosted by Universität für Bodenkultur Wien, the meeting featured valuable updates
Services
SDGs
As a company committed to sustainability, we follow the UN’s 2030 Agenda and its Sustainable Development Goals.
Memberships & PartnershipS
Quality Management System
Innovative SME
SDGs
As a company committed to sustainability, we follow the UN’s 2030 Agenda and its Sustainable Development Goals.
© Asphalion
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
